Multiple sclerosis has traditionally been described as a demylinating disorder. There is now overwhelming evidence pointing to a very significant degenerative component. Current treatment options include immunomodulating and immunosuppressive agents as well as monoclonal antibodies and target the inflammatory ...
Treating multiple sclerosis costs a great deal for patients and communities. Individually, the nearly 1 million people with MS pay an average annual cost of more than $88,000 for the various treatment options, devices, daily living needs, and insurance needed for their condition. Overall, indirec...
An increasing number of children and adolescents with multiple sclerosis (MS) are being identified and treated with disease-modifying therapies. Yet, there
Primary progressive multiple sclerosis : current and future treatment options. LEARY SIOBHAN M ET AL: " Primary progressive multiple sclerosis : current and future treatment options. " CNS DRUGS 2005, vol. 19, no. 5, 2005, ... SM Leary,AJ Thompson - 《Cns Drugs》 被引量: 96发表: 2005年...
Low- or moderate-effectiveness treatment agent MAD: Multiple ascending dose MBP: Myelin basic protein MHC: Major histocompatibility complex MOG: Myelin oligodendrocyte glycoprotein MRI: Magnetic resonance imaging MSC: Mesenchymal stem cell MS: Multiple sclerosis ...
Multiple sclerosis, an autoimmune disorder causing the destruction of the impulse carrying myelin sheath of neurons, can be a debilitating and disabling disease. Symptomatic treatment has provided patients with relief through the use of antispasmodics, anticholinergics, and antidepressants, just to name ...
While not all multiple sclerosis (MS) relapses require treatment, relapses that are bothersome or that impair function should prompt consideration of timel
Recent scientific advances have led to improved therapies for multiple sclerosis (MS). Current therapies are aimed at decreasing the damage incurred by neurons as well as attempting to restore proper function. However, all of the Food and Drug Administration (FDA) approved therapies are only indicat...
Multiple sclerosis is an autoimmune disease in which T cells attack oligodendroglial cells in the CNS causing demyelination of neurons and failure of normal axonal conduction. Multiple sclerosis tends to be a relapsing and remitting disease in which localized areas in the brain are targeted at diffe...
A review of the literature on treating multiple sclerosis (MS) aims to provide physicians with evidence-based information on the latest treatments for this chronic disease. The article, published inCMAJ(Canadian Medical Association Journal) looks at the latest pharmacologic research as well as disease...